Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.

Middleton, M; Hauschild, A; Thomson, D; Anderson, R; Burdette-Radoux, S; Gehlsen, K; Hellstrand, K; Naredi, P

Middleton, M; Hauschild, A; Thomson, D; Anderson, R; Burdette-Radoux, S; Gehlsen, K; Hellstrand, K; Naredi, P.

Affiliation

Middleton M; Department of Medical Oncology, Christie Hospital, Manchester, UK.

Ann Oncol ; 18(10): 1691-7, 2007 Oct.

Article in En | MEDLINE | ID: mdl-17709802

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Dacarbazine/administration & dosage; Histamine/administration & dosage; Interferon-alpha/administration & dosage; Interleukin-2/administration & dosage; Melanoma/drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Dacarbazine/adverse effects; Female; Histamine/adverse effects; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha/adverse effects; Interleukin-2/adverse effects; Male; Melanoma/mortality; Melanoma/pathology; Middle Aged; Multivariate Analysis; Neoplasm Staging; Recombinant Proteins

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Histamine / Interleukin-2 / Interferon-alpha / Dacarbazine / Melanoma Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2007 Type: Article Affiliation country: United kingdom

Search on Google

XML

PubMed Links